Key Highlights
- Nura Bio closes $140M Series A financing to support clinical development.
- Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success of NB-4746.
- NB-4746 is a brain-penetrant SARM1 inhibitor with potential neuroprotective benefits.
- Phase 1 trial results show NB-4746 was well-tolerated and achieved target plasma exposure.
Source: Business Wire
Notable Quotes
- “Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies.” — Tim Kutzkey, Ph.D., Managing Partner at The Column Group
- “I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025.” — Shilpa Sambashivan, Ph.D., CEO at Nura Bio
SoHC's Take
The successful closing of over $140M in Series A financing for Nura Bio underscores the increasing investor confidence in the company’s neuroprotective research and therapeutic pipeline. With NB-4746 progressing successfully through Phase 1 trials, Nura Bio is well-positioned to address significant unmet needs in the treatment of neurological diseases. Shilpa Sambashivan’s appointment as CEO is a strategic move, leveraging her deep scientific expertise and leadership to guide the company toward achieving its ambitious clinical milestones in the coming years.
Heading
Key Highlights Ginkgo Bioworks releases first proprietary protein LLM, trained on exclusive datasets.Collaboration with Google Cloud enables AI-driven drug discovery tools.Open API allows researchers to access Ginkgo’s machine ...
Key Highlights Courtney Green joins QGenda as Vice President of Nurse and Staff Solutions.Brings over 20 years of clinical and operational leadership experience.Focus on optimizing ...
Key Highlights Vyne Medical® acquires Extract Systems®, a leader in data extraction solutions.Accelerates healthcare automation by integrating AI and machine learning ...
Key Highlights PatientPay integrates with Azalea Health’s API to streamline patient billing for ambulatory providers.Faster revenue capture with less than 14 days to payment, ...
Key Highlights Partnership streamlines revenue cycle management for ABA therapy providers.Flychain’s financial tools offer real-time insights, secure funding, and automation.Raven ...
Key Highlights Nura Bio closes $140M Series A financing to support clinical development.Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success ...
